Oculis Eyes Opportunities With Fresh Funding and Novartis Licensing Deal
Executive Summary
As Novartis looks to move out of much of its ophthalmology research with the forthcoming spinoff of Alcon, fellow Swiss firm Oculis has licensed one of its assets and secured new financing to progress its back-of-the-eye treatments.
You may also be interested in...
Deal Watch: Sanofi Retains Options To Two Bispecifics While Exiting Antibody Pact With Regeneron
Sanofi and Regeneron terminate the immuno-oncology partnership signed in 2015, but will continue to collaborate on Libtayo. Biogen signs a pair of partnerships in CNS disorders, with C4 and Skyhawk, and more deals from the first day of the J.P. Morgan conference.
Finance Watch: Former Juno Execs Launch Sana With Allogeneic Cell Therapy Platform
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
Narasimhan: Novartis' Specialized Portfolio Will Lead To Bigger Breakthroughs And Greater Value
At Novartis’s first R&D day since he took the helm, new CEO Vas Narasimhan told Scrip about how the company plans to build value through its newly acquired breakthrough technologies and what deals it is looking for next.